Merck & Co., Inc. (MRK) belongs to the “Healthcare” sector with an industry focus on “Drug Manufacturers – Major”, with Mr. Kenneth C. Frazier as Chairman, Chief Exec. Officer and Pres.
The company has been one of the biggest innovators in “Drug Manufacturers – Major” employing approximately 67455 full time employees.
- The stock added in the prior trading session by 1.41%, closing at the stock price of $63.89.
- Currently, the market capitalization of Merck & Co., Inc. (MRK) is 174.75 Billion.
- MRK has a 1-year high price of $ 66.32 and 1-year low price of $52.47.
- The number of shares currently held by investors is 2.74 Billion.
- The number of shares traded in the last trading session was 11.95 Million.
The company reported an impressive total revenue of 39.81 Billion in the last fiscal year.
If you look at the company’s income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, MRK earned gross profit of 31.25 Billion, in 2015 29.67 Billion gross profit, while in 2016 Merck & Co., Inc. (MRK) produced 30.14 Billion profit.
Currently the shares of Merck & Co., Inc. (MRK) has a trading volume of 11.95 Million shares, with an average trading volume of 10570 shares – with shares dropping to a 52 week low of $52.47, and the company’s shares hitting a 52 week high of $ 66.32.
Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Down in the future.
Earnings per share (EPS) breaks down the profitability of the company on a single share basis, and for Merck & Co., Inc. the EPS stands at 0.88 for the previous quarter, while the analysts predicted the EPS of the stock to be 0.83, suggesting the stock exceeded the analysts’ expectations.
Another critical number in evaluating a stock is P/E or the price to earnings ratio.
Currently the P/E of Merck & Co., Inc. stands at 40.93. Looking at this figure it suggests that the shares of Merck & Co., Inc. (MRK) may be overvalued, however, this can also depend upon the situation of the market; if the market is strong then it could suggest that Merck & Co., Inc. (MRK) is a good investment, however if the market is weaker then it could suggest that the shares are undervalued.
The TTM operating margin is 14.4%. The return on invested capital at 6.2%, which is good, compared to its peers.
The Free Cash Flow or FCF margin is 104.74%, which means that the business has healthy reserve funds for contingencies that may arise.
Stock is currently moving with a positive distance from the 200 day simple moving average of approximately 3.18%, and has a solid year to date (YTD) performance of 9.31% which means the stock is constantly adding to its value from the previous fiscal year end price.
The stock diminished about -0.04% in the past 5 years, this negative value indicates that the stock constantly going down in previous years as well.
The target price for Merck & Co., Inc. (MRK) is $69.53/share according to the consensus of analysts working on the stock, with an expected EPS of $0.87/share for the current quarter.
The company’s expected revenue in the current quarter to be 9.67 Billion, seeing a projected current quarter growth of -6.5%, and per annum growth estimates over the next 5 year period of around 6.02%.